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Article

Hyperfiltration Affects Accuracy of Creatinine eGFR
Measurement
Shih-Han S. Huang,* Ajay P. Sharma,† Abeer Yasin,† Robert M. Lindsay,* William F. Clark,* and Guido Filler†

Summary
Background and objectives Surrogate markers such as creatinine, cystatin C (CysC), and beta trace protein
(BTP) have been used to estimate GFR (eGFR). The accuracy of eGFR may be altered with hyperfiltration
and differences in filtration fraction (FF). It is hypothesized that the accuracy of creatinine for eGFR may be
affected by hyperfiltration and different effective renal plasma flow (ERPF).
Design, setting, participants, & measurements A total of 127 pediatric patients with various renal diseases
underwent simultaneous measurements of GFR using 51Cr-EDTA renal scan and ERPF (131I-hippurate
clearance) to calculate the FF (FF ⫽ GFR/ERPF). The eGFRs were calculated using the commonly used
Schwartz (creatinine), Filler (CysC), and Benlamri (BTP) formulas. Agreement of the eGFRs with the measured isotope GFRs was assessed by Bland–Altman plots. Correlation analysis was performed using nonparametric tests to compare FF with eGFR ⫺ GFR.
Results The 127 children at a median age (with 25th percentile, 75th percentile) of 11.9 (8.5, 14.9) years had
a mean 51Cr EDTA-GFR of 100.6 ⫾ 32.1 ml/min per 1.73 m2 and a median 131I-hippurate clearance (ERPF)
of 588 (398,739) ml/min per 1.73 m2. Mean FF was 17.7 ⫾ 4.5% with no correlation between the FF and the
error (eGFR ⫺ GFR) for CysC and BTP eGFR, whereas there was a significant negative correlation between
the error for Schwartz eGFR and FF.
Conclusions There is a significant negative correlation between the error for the Schwartz eGFR and the FF.
CysC and BTP are not affected by differences in FF.
Clin J Am Soc Nephrol 6: 274 –280, 2011. doi: 10.2215/CJN.02760310

Introduction
Renal function measurement is often focused on the
GFR and, to a lesser extent, on renal blood flow (1).
The gold standard for measuring GFR is inulin
clearance (2). However, nuclear medicine studies
have replaced inulin clearance because of convenience and absence of urine collection. In Europe,
51
Cr-EDTA is the most widely used method for the
determination of GFR (3), whereas in North America, the 99Tc-diethylenetriamine pentaacetic acid renal scan enjoys the most widespread utilization
(3–5). Although less demanding than inulin clearance studies, nuclear GFR studies are still cumbersome, invasive, and involve radiation. Endogenous
markers for estimated GFR (eGFR), such as serum
creatinine and more recently cystatin C (CysC), are
hampered by diagnostic imprecision (6). Recently
beta trace protein (BTP) has been introduced as a
surrogate marker for GFR measurement (7).
Creatinine (molecular weight ⫽ 113 D, neutrally
charged) is the metabolic product of creatine and
phosphocreatine found in muscle; therefore, it reflects
muscle mass (8,9). Given the large variability of muscle mass, there is substantial interpatient variability of
serum creatinine concentration (10) because of its
high water solubility (11).
274
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Serum CysC has been shown to be an excellent
marker for GFR (6,12,13). It is a small-molecularweight protein (molecular weight ⫽ 13 kD, positive
charge with isoelectric point of 9.3) that was initially
known as ␥-trace protein and its amino acid sequence
was determined in 1981 (14,15). This protein is produced at a very constant rate and is affected by only
a few conditions, such as uncontrolled hyperthyroidism (16).
BTP (molecular weight ⫽ 23 to 29 kD, mildly negatively charged with isoelectric point of 5.8 to 6.7, also
known as prostaglandin D synthase) has been traditionally used as a marker of cerebrospinal fluid leakage (17,18). It is expressed in all tissues except the
ovaries (19). Preliminary studies have confirmed a
good correlation between serum BTP levels and GFR
measurement by inulin clearance and nuclear medicine techniques (5,20).
Hyperfiltration is considered an abnormal increase
in the GFR (21,22). However, this definition ignores
the fact that hyperfiltration can take place in a single
nephron even with globally decreased GFR. Other
sources have defined hyperfiltration as the result of
an increase in the glomerular capillary pressure
(23,24). The filtration fraction (FF) is the ratio of GFR
and effective renal plasma flow (ERPF) (24). A normal
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FF is 18.7 ⫾ 3.2% in healthy young adults between the
ages of 20 and 30 years (25). Hyperfiltration should be
considered if the FF is above the reference interval.
We were interested in whether hyperfiltration affects the diagnostic accuracy of commonly used eGFR
measurements using creatinine, CysC, and BTP in a
pediatric population. The precision between the surrogate markers and the eGFR is reduced at higher
GFR. One possible explanation for this phenomenon
may be that some patients hyperfilter and others do
not.

Patients and Methods
Patients
The study received full approval of the local ethics
boards and was in accordance with the ethical standards of the Helsinki declaration of 1975 (revised in
1983) (5). Written consent was obtained in each case
from the parents and, in the case of a consenting
minor, from the patients as well. One hundred twentyseven of the patients had a 51Cr-EDTA renal scan with
concomitant determination of the 131I-hippurate clearance (ERPF), thus allowing for the calculation of the
FF. Venous blood samples were obtained from 127
children with various renal pathologies, referred for
determination of nuclear medicine GFR study. Patients were recruited consecutively and their ages
ranged from 1.0 to 18.0 years with a mean of 11.5 ⫾
4.2 years. Thirty-five percent of patients were girls.
Mean height was 136.7 ⫾ 28.4 cm (range 62.3 to 189.1
cm), mean weight was 40.2 ⫾ 20.0 kg (range 6.5 to
104.0 kg), and mean body surface area was 1.22 ⫾ 0.42
m2 (range 0.33 to 2.20 m2). The main indications for
GFR measurements were various forms of GN
(44.7%), obstructive uropathy (19.9%), reflux nephropathy (13.6%), postrenal transplantation (5.4%),
and others (16.4%, including posthemolytic uremic
syndrome, steroid-sensitive nephrotic syndrome, cystinosis, orthostatic proteinuria, etc.).

Materials and Methods
The methods for the simultaneous measurement of
GFR and ERPF using 51Cr-EDTA renal scan with concomitant determination of the 131I-hippurate clearance have been described elsewhere (25). GFR and
ERPF were corrected to a standard body surface area
of ml/min per 1.73 m2. For consistency, by GFR and
ERPF we mean the corrected values per 1.73 m2 of
body surface area throughout the manuscript. FF was
calculated as the ratio between 51Cr-EDTA GFR and
131
I-hippurate ERPF and was expressed in percent.
Serum creatinine was measured with an enzymatic
assay (Ortho Clinical Diagnostics). Because enzymatic
assays measure approximately 20% lower than the
Jaffé method that was used in the original formula by
George Schwartz (26), we used 20% higher constants
(38 for children ⬎1 year of age, 48 for adolescent boys)
to calculate the GFR estimate according to Schwartz.
We validated these revised constants for the Schwartz
formula in our patient cohort. For adolescent boys,
the estimated constant was 49.4 ⫾ 10.5, not signifi-
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cantly different from 48 (P ⫽ 0.3271, one-sample t
test). For the nonadolescent male patients, the constant was 40.3 ⫾ 7.7, again not significantly different
from 38. We therefore used the constants of 38 and 48.
The formula reads

GFRestimate ⫽

height (cm) ⫻ constant
serum creatinine (  mol/L)
(1)

The methods for the determination of CysC (Siemens
Diagnostics GmbH) and BTP (Siemens Diagnostics)
were described in the previous study (5). CysC eGFR
was calculated using the Filler formula (27). For the
BTP eGFR, we used a recently published and validated formula by Benlamri et al. (28).
We calculated the error between the measured GFR
and the eGFR for creatinine using Schwartz, CysC,
and BTP using (eGFRParameter ⫺ measured GFR)/measured GFR.
Statistical Analyses
All statistical analyses were performed using
GraphPad Prism Software for Science Version 4.0c
(San Diego, CA). Standard regression and correlation
analyses were applied. Normal distribution was assessed using the Shapiro–Wilk test.
Agreement between methods was tested using the
Bland–Altman plot method (29). The Bland–Altman
plot is a statistical method used to compare two measurement techniques. In this graphical method, the
differences (or alternatively the ratios) between the
two techniques are plotted against the averages of the
two techniques. Horizontal lines are drawn at the
mean difference, and at the mean difference ⫾ 1.96
times the SD of the differences. If the differences
within the mean ⫾ 1.96 SD are not clinically important, the two methods may be used interchangeably.
SD of the differences between the two assay methods
is used to calculate the limits of agreement, computed
as the mean bias ⫾ 1.96 times its SD. The bias is
computed as the value determined by one method
minus the value determined by the other method. If
one method is sometimes higher, and sometimes the
other method is higher, the average of the differences
will be close to zero. If it is not close to zero, this
indicates that the two assay methods are producing
different results. Correlation analysis was performed
using appropriate parametric (in case of normal distribution) or nonparametric tests (Spearman rank). In
the case of non-normal distribution, data are given as
a median (25th percentile, 75th percentile). The percentiles in brackets are also known as the interquartile
range (IQR). P ⬍ 0.05 was considered statistically
significant.

Results
The 127 children had a median age of 11.9 (IQR 8.5,
14.9) years, weighed 39.9 (28.8, 54.3) kg, and had a
height of 146.0 (131.0, 163.8) cm. Mean body surface
area was 1.30 ⫾ 0.39 m2. The mean measured 51Cr-

0.988
0.332
0.6735
P ⬍ 0.0001
0.9806
0.0648
0.8616
P ⬍ 0.0001
0.9466
P ⬍ 0.0001
0.9567
0.0005
0.9857
0.2032
0.9104
P ⬍ 0.0001

127
81.67
103.4
126
102.4
31.35
127
0.62
0.76
0.98
0.8935
0.4774
127
73.97
93.72
113
91.27
27.8
127
0.83
0.98
1.21
1.105
0.376
127
84.5
108.7
134.6
112.4
37.86
127
41.55
55.69
74.26
58.76
23.26
127
14.6
17.4
20.3
17.7
4.5
127
398
588
739
614
296.5

EDTA GFR was 100.6 ⫾ 32.1 ml/min per 1.73 m2. The
median 131I-hippurate clearance (ERPF) was 588 (398,
739) ml/min per 1.73 m2. The mean FF was 17.7 ⫾
4.5%. Median serum creatinine was 56 (52, 74)
mol/L, whereas median CysC was 0.98 (0.83, 1.21)
mg/L and median BTP was 0.76 (0.62, 0.98) mg/L.
The results of the most important parameters are
summarized in Table 1.
Bland–Altman analysis revealed a bias of 10.8% ⫾
21.2%, with a 95% limit of agreement from ⫺0.8% to
52.4% between the Schwartz formula eGFR and the
measured GFR. For CysC, the bias was ⫺9.6% ⫾
21.6% with a 95% limit of agreement from ⫺52.0% to
32.7%, and for BTP the bias was 1.4 ⫾ 28.3 with a 95%
limit of agreement from ⫺54.0% to 56.8% (Table 2).
The median (IQR) relative error (eGFR ⫺ GFR/
GFR) for the Schwartz formula was ⫹12 (IQR ⫺4,
⫹24)%, whereas the median error for CysC eGFR was
⫺9 (IQR ⫺21, ⫹6)%, and for BTP eGFR was ⫹5 (IQR
⫺16, ⫹25)% (Table 3).
There was no correlation between the FF and the
error for CysC eGFR and BTP eGFR, whereas there
was a significant negative correlation between the
error for the Schwartz eGFR and the FF (Figure 1).
Furthermore, a significant negative correlation existed between FF and GFR, Schwartz GFR, CysC
eGFR, and BTP eGFR. Clinically, this suggests that
most patients with a lower GFR hyperfilter, whereas
only some hyperfilter with normal GFR.
Table 4 summarizes the correlation analysis (Spearman rank). There was no significant correlation between the error for the CysC eGFR and BTP eGFR and
the FF. On the other hand, a significant negative correlation existed between FF and GFR, Schwartz GFR,
CysC eGFR, and BTP eGFR.

Discussion
The main finding of the study was that creatininebased eGFR was influenced by the FF, whereas the
accuracy of the eGFR from the Filler equation using
serum CysC and the Belamri equation using serum

0.9843
0.1501

127
77
97
121
100.6
32.08

Table 2. Bland–Altman results summarized for agreement
of various eGFR formulas with the measured isotope GFR

Number
25th Percentile
Median
75th Percentile
Mean
SD
Shapiro–Wilk normality test
Wilk constant
P

51
Cr-EDTA
(ml/min per
1.73 m2)

123

I-Hippurate
(ml/min per
1.73 m2)

FF (%)

Creatinine
(mol/L)

Schwartz eGFR
(ml/min per
1.73 m2)

CysC
(mg/L)

CysC eGFR
(ml/min per
1.73 m2)

BTP
(mg/L)

BTP eGFR
(ml/min per
1.73 m2)
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Table 1. Statistics of the most important measured and calculated parameters
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Formula

Schwartz
eGFR

Cystatin C
eGFR

BTP
eGFR

Bias
10.8
9.6
1.4
SD %
21.2
21.6
28.3
95% Limit of ⫺0.80 to 52.4 ⫺52.0 to 32.7 ⫺54.0 to 56.8
agreement

Table 3. Error by level of eGFR (eGFR ⴚ GFR/GFR) for
various eGFR formulas

Formula
Median error
25th percentile error
75th percentile error

Schwartz Cystatin C BTP
eGFR
eGFR
eGFR
⫹12.0
⫺4.0
⫹24.0

⫺9.0
⫺21.0
⫹6.0

⫹5.0
⫺16.0
⫹25.0
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Figure 1. | The relationship between the percentage error of the Schwartz formula eGFR and the measured GFR plotted against
the FF. There was a significant negative correlation (Spearman r ⫽ ⫺0.2365, P ⫽ 0.0074). For the nonlinear regression model,
we used a one-phase exponential decay model with the constants SPAN ⫽ 2295, K ⫽ 0.0001440, PLATEAU ⫽ ⫺2295, and
HalfLife ⫽ 4815.
Table 4. Spearman rank correlations between the error of the GFR estimate models (BTP, CysC, Schwartz) with FF

Parameter

Schwartz Percent Error

CysC Percent Error

BTP Percent Error

Number of xy pairs
Spearman r
95% Confidence interval
P value (two-tailed)
P value summary

127
⫺0.2365
⫺0.3988 to ⫺0.05968
0.0074
Significant

127
⫺0.08541
⫺0.2607 to 0.09535
0.3397
NS

127
⫺0.1089
⫺0.2826 to 0.07185
0.2232
NS

NS, not significant.

BTP was unaffected. In fact, there was a significant
negative correlation between error of eGFR calculated
from the Schwartz formula and the measured GFR
and the FF. To the best of our knowledge, this is the
first study that demonstrates that the error between
Schwartz formula eGFR and measured GFR is altered
by hyperfiltration. By contrast, eGFR based on lowmolecular-weight proteins was not altered by hyperfiltration.
This finding is novel and has significant implications. Previous studies have focused on the errors in
eGFR from various surrogate markers and their respective formulas to the nuclear GFR studies (30 –32).
Better agreement was consistently found in the low
GFR range, whereas the precision between measured GFR and surrogate marker eGFR worsened
with normal and high GFR values (24,30). It was
therefore logical to assess the effect of hyperfiltration on the diagnostic performance of surrogate
eGFR markers. Previous studies did not include
ERPF or FF.
What does this mean? It appears that a small-molecular-weight soluble substance can be affected by
hyperfiltration, which weakens its diagnostic performance as a GFR marker, whereas low-molecularweight proteins are unaffected. This would render
serum creatinine a less accurate marker for eGFR in
the presence of hyperfiltration. Because GFR may remain constant in the early stages of chronic kidney
disease whereas the nephron endowment deteriorates
secondary to a renal disease, patients with a normal
GFR may or may not be hyperfiltrating. In advanced

chronic kidney disease, all remaining nephrons hyperfilter (33). It is therefore conceivable that the degree of hyperfiltration may serve as the main explanation for the reduced precision of any surrogate GFR
marker in the normal and high GFR range. Admittedly, the correlation was only 0.24, which was significant, but not very impressive. The study was not
designed to discover a strong correlation between the
error of a creatinine-based eGFR formula and the FF;
rather, it was designed to test the hypothesis whether
some of the variance of the scatter can be explained by
the degree of hyperfiltration. The clinical significance
of our findings lies in the fact that hyperfiltration can
indeed explain some of the imprecision of creatininebased eGFR, and patients early in the course of diabetic nephropathy and IgA nephropathy may especially have significant hyperfiltration. In the low GFR
range, the phenomenon becomes less important, but
our data suggest that creatinine handling may be
altered by the FF to a degree that it renders the marker
less favorable when compared with the low-molecular-weight eGFR markers.
Of course, the question arises as to why the small
molecule creatinine is handled differently than the
small-molecular-weight proteins CysC and BTP. All
surrogate eGFR markers have different charges and
isoelectric points. Because CysC and BTP are handled
identically, electric charge is unlikely to explain the
negative correlation between the error in eGFR for
creatinine in the measurement of the FF. One possible
explanation for this increase in error in creatininebased eGFR using the Schwartz formula is that creat-
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Figure 2. | The relationship between the FF and efferent blood flow. When the FF decreases, there is an increase in efferent blood
flow and creatinine availability. This will lead to an increase in tubular secretion.

inine is also secreted by the renal tubule along with
the excretion from glomerular filtration, whereas
there is minimal or no tubular reabsorption of creatinine (34). CysC and BTP are exclusively eliminated
through glomerular filtration. Therefore, with low FF,
there is more blood flow in the efferent arteriole and
subsequently more creatinine available in the peritubular capillaries for tubular secretion. This may lead
to an increase of tubular secretion at lower FF, thereby
creating an overestimation in the eGFR. It should be
noted that the difference between the 25th and 75th
percentile (i.e., IQR, a measure of precision) was inferior for BTP, suggesting that of the two low-molecular-weight proteins, CysC should be preferred.
When the FF is increased, there is a decrease in
efferent blood flow with a subsequent decrease of
creatinine available for tubular secretion. Therefore,
the eGFR from the creatinine-based formula correlates better with measured GFR at higher FF. The
proposed differential handling of creatinine with
lower and higher FF is demonstrated in Figure 2.
Because tubular secretion does not modify CysC and
BTP concentrations, the FF is unaffected by the error
between the eGFR errors for CysC and the BTP-based
formulas.
Our study has limitations. The first limitation is
related to the nuclear medicine methods chosen to
determine GFR and ERPF. No separate gold standard
such as inulin clearance and para-aminohippuric acid
(PAH) clearance were used to evaluate the accuracy
of the nuclear medicine methods. Nuclear medicine
methods are known to be imperfect measures of GFR
and ERPF. Inulin and PAH clearance studies are no
longer performed in most tertiary centers. However,
the methods were validated and performed as described in reference 25 as the standard of care. Although earlier studies comparing inulin clearance and
51
Cr-EDTA clearance mostly reported correlations
upon introduction of the nuclear medicine methods, a
recent study from Medeiros et al. used appropriate

testing for agreement with Bland–Altman analysis for
an identical method to ours and revealed narrow
limits of agreement and a difference (bias) of 2.8 and
2.7 ml/min, respectively. They concluded that 51CrEDTA clearance was a reliable method to measure
GFR compared with inulin clearance (35). We are
unaware of any modern studies using Bland–Altman
analysis to study agreement between 131I-hippurate
clearance with PAH clearance; however, a study from
1980 demonstrated identical results with PAH clearance and slightly better performance of the 131I-hippurate clearance that we used in our study when
compared with PAH clearance (36). Furthermore, this
study was conducted in a pediatric population and it
is unclear whether these findings can be generalized
to all ages. In children, eGFR is calculated using the
Schwartz formula that is based on creatinine and
patient height. Adult eGFR calculations based on serum creatinine, such as the Modification of Diet in
Renal Disease study equation and the Cockcroft–
Gault equation, require additional information such
as age, weight, gender, and ethnicity. In children,
these formulas cannot be used (37). Before the findings of this study can be generalized, the increased
eGFR errors that occur at lower FF will need to be
confirmed in adult populations using adult eGFR
equations that are based on serum creatinine.
The eGFR errors using the Schwartz formula
change with the state of FF. It is impractical to measure FF in every patient. FF can only be measured if
GFR and ERPF are determined simultaneously. In
Canada, 131I or 121I-PAH are not commercially
available. Furthermore, for a simultaneous nuclear
medicine method, two different isotopes with ␥ and
␤ radiation are required, which is impractical in
North America because 51Cr-EDTA is not commercially available (38). Although we have a general rule
of thumb that the tubular secretion for creatinine is
approximately 10% of the total excretion (34), this
may not be applicable for different degrees of hyper-
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filtration. The creatinine-based eGFR formulas may
be unpredictable in terms of the eGFR errors. Other
limitations include a relatively low sample size of 127
patients and a small proportion of patients with low
GFR. Our study casts significant doubts on the accuracy of serum creatinine in patients with a variable
degree of hyperfiltration. Early in the course of disease, hyperfiltration may or may not be operant. In
the case of a GFR ⬎150 ml/min per 1.73 m2, hyperfiltration can be assumed, but in the case of normal
GFR, hyperfiltration may or may not occur. Our study
suggests that a surrogate marker for eGFR should be
based on a low-molecular-weight protein rather than
on serum creatinine.
The question of the clinical applicability of these
findings remains to be established. Short of performing a proper inulin and PAH clearance study, FF is
not easily measurable. Clinically, we assume hyperfiltration whenever the GFR is high. Our study also
suggests that all patients with a low GFR hyperfilter.
The importance of this study lies less in the clinical
applicability of the effect of hyperfiltration on creatinine excretion, but more points to an important factor
that explains some of the scatter when using surrogate markers for the estimation of eGFR. The study
also suggests that CysC is less affected by hyperfiltration than creatinine.
In conclusion, this study showed that the creatinine-based Schwartz formula is influenced by FF. The
errors of eGFR negatively correlate with FF. Only the
eGFRs based on low-molecular-weight proteins
(Filler equation using CysC and the Belarmi equation
using BTP) are unaffected at different levels of FF.
Further studies are required to test the result in adult
populations with other creatinine-based formulas.
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